Highlights of weekly biotech stock moves

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) fell $0.60 (41%) to $0.87 on Tuesday after it said FDA recommended the company conduct an additional trial for Northera droxidopa to support an NDA resubmission to treat neurogenic orthostatic hypotension. Then on Friday, the stock jumped $0.38 (42%) to $1.28 after Chelsea received a letter from shareholder Josiah Austin urging the company to explore strategic alternatives. Austin has a 12.39% stake (see B9).

The stock was down $0.20 (14%) last week...